These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 9410815)

  • 1. [Pertussis vaccination with acellular vaccines. Tolerance--effectiveness--current vaccination recommendations].
    Liese JG; Stojanov S; Belohradsky BH
    Fortschr Med; 1997 Aug; 115(24):22-7. PubMed ID: 9410815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.
    Taranger J; Trollfors B; Bergfors E; Knutsson N; Sundh V; Lagergård T; Lind-Brandberg L; Zackrisson G; White J; Cicirello H; Fusco J; Robbins JB
    Clin Infect Dis; 2001 Oct; 33(7):1004-10. PubMed ID: 11528572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boostrix: a reduced-dose acellular pertussis vaccine for use in adolescents and adults.
    Li WC; Wu TZ; Huang YC; Huang LM
    Expert Rev Vaccines; 2009 Oct; 8(10):1317-27. PubMed ID: 19803753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
    Wilson TR
    J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
    Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
    Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan.
    Sato H; Sato Y
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S124-30. PubMed ID: 10447030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acellular pertussis vaccine].
    Wiedermann G; Ambrosch F; Vanura H
    Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal, recommendations.
    Gardner P
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S131-5. PubMed ID: 10447031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components.
    Zieliński A; Rosińska M
    Przegl Epidemiol; 2008; 62(3):589-96. PubMed ID: 19108523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertussis--United States, 1997-2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Feb; 51(4):73-6. PubMed ID: 11837909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The immunological basis of the administration of DTP-polio vaccine].
    Cohen H
    Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Can we control pertussis better? II. Old and new vaccines against pertussis].
    Gałazka A
    Przegl Epidemiol; 1997; 51(3):285-95. PubMed ID: 9411499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.